Susan Ruediger on Pursuing Gene Therapies for CMT

Video

Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the foundation’s mission.

“Our job at the Research Foundation is to bring CMT to the forefront of everybody's mind, and then to bring a little bit of funding along with it to motivate people to get involved. And without that effort, and without that focus, if not us, then who? And if not now, then when? So that's the perspective that patients like me can bring is that sense of urgency and the sense of organization.”

As more companies explore gene and cell therapies for rare diseases like Charcot-Marie-Tooth (CMT) disease and others, the importance of collaboration between industry, academics, and patient advocacy groups has become more and more apparent to successfully develop and evaluate these therapies.

The nonprofit company CMT Research Foundation is working to help researchers find treatments for CMT. Susan Ruediger, the company’s founder and chief mission officer, who herself has CMT, recently participated in a discussion entitled “Partnering for Progress”, on this topic during the 2022 BIO International Convention, held June 13-16 in San Diego, California.

CGTLive spoke with Ruediger to learn more about the CMTRF and its mission. She also discussed how having CMT herself has driven her to found the company and the unique perspectives patients can bring to therapy research and development.

REFERENCE
Schmidt H, Ruediger S, et al. Partnering for progress: Collaborating with patient organizations to advance therapy development and maximize patient benefit. Presented at: 2022 BIO International Convention, June 13-16, San Diego, CA.
Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.